Advances in Veterinary Drug Delivery

Advances in Veterinary Drug Delivery

This title investigates new avenues of drug delivery for new and existing products and discusses which delivery systems are most effective for oral, parenteral, pulmonary and topical drug administration.

This report examines drug delivery systems and formulations for both the livestock and companion animal sectors, supplying up-to-date information on the types of delivery suited to each area. It discusses the latest drug delivery mechanisms, enabling you to compare different delivery methods and their efficacy in use.

Advances in Veterinary Drug Delivery examines the ways in which drug delivery is strategically employed to add commercial value to products nearing patent expiry. The report includes profiles of drug delivery specialists with recent, current or potential involvement in the animal health sector.

Profiles include detailed information on:

* company background
* financial results
* new technologies
* animal health applications
* partnerships
* future developments

Companies profiled: Aquila Biopharmaceuticals; Atrix Laboratories; Captec; CollaGenex; Embrex; Emisphere Technologies; Endorex; Fuisz Technologies; Mycogen; PowderJect; Scherer; Virus Research Institute.

PUBLISHED: JULY 1998
REF: SR175E
PAGES: 102
PRICE: £395/$830/¥95,000

CONTENTS
LIST OF TABLES

CHAPTER 1 INTRODUCTION
1.1 Routes of administration
1.1.1 Oral administration
1.1.2 Parenteral administration
1.1.3 Pulmonary administration
1.1.4 Topical administration
1.2 Conventional delivery methods
1.2.1 Refining drug delivery methods
1.3 New directions in drug delivery
1.3.1 Long-acting preparations
1.3.2 Sustained release hardware
1.3.3 Coating and 'taste-masking' technologies
1.3.4 Vaccine delivery
1.3.5 New delivery routes and methods
1.4 Drug delivery as a commercial strategy
1.5 Drug delivery companies

CHAPTER 2 DELIVERY SYSTEMS AND FORMULATIONS IN THE MAJOR PRODUCT SECTORS
2.1 Anthelmintics and endectocides
2.1.1 Key delivery systems and formulations
2.1.2 Recent developments
2.2 Ectoparasiticides
2.2.1 Key delivery systems and formulations
2.2.2 Recent developments
2.3 Antimicrobials
2.3.1 Key delivery systems and formulations
2.3.2 Recent developments
2.4 Other pharmaceuticals
2.4.1 Reproductive products
2.4.2 Non-steroidal anti-inflammatory drugs
2.4.3 Companion animal dental treatments
2.5 Growth promoters and performance enhancers
2.5.1 Key delivery systems and formulations
2.5.2 Recent developments
2.6 Vaccines
2.6.1 Key delivery systems and formulations
2.6.2 Recent developments

CHAPTER 3 CURRENT DEVELOPMENTS & NEW DIRECTIONS
3.1 Oral drug delivery
3.1.1 Oral delivery of macromolecules
3.1.2 Microsphere technology
3.1.3 Rapid-dissolving dose forms
3.1.4 Transmucosal patches
3.2 Vaccine delivery
3.2.1 Adjuvant technology
3.2.2 Oral and mucosal vaccines
3.2.3 DISC-virus technology
3.2.4 Chimaeric viral particle technology
3.2.5 Edible vaccines
3.2.6 In ovo vaccination
3.3 Depots, implants and needle-free injections
3.3.1 Injectable depots and implants
3.3.2 Needle-free injection
3.4 Implantable devices
3.4.1 Antiparasitic bolus products
3.4.2 Reproductive implants
3.5 The future for veterinary drug delivery
3.5.1 Current activity in the drug delivery industry
3.5.2 Future developments in the companion animal sector
3.5.3 Future developments in the food animal sector

CHAPTER 4 STRATEGIC CONSIDERATIONS
4.1 Strategic advantages of delivery systems
4.1.1 Improved therapy or prophylaxis
4.1.2 Easier administration
4.1.3 Extending product life-cycles
4.1.4 Branding a generic product
4.2 Accessing drug delivery capability
4.2.1 Building in-house resources
4.2.2 Licensing technology
4.3 The drug delivery industry
4.3.1 Development of the drug delivery sector
4.3.2 Drug delivery companies and the animal health sector
4.3.3 Animal health companies and the drug delivery sector
4.4 Licensing delivery technology
4.4.1 Product and technology choice
4.4.2 Choosing a partner
4.4.3 Negotiations and agreements

CHAPTER 5 COMPANY PROFILES
5.1 Aquila Biopharmaceuticals
5.1.1 Background
5.1.2 Technology
5.1.3 Animal health applications
5.1.4 Future developments
5.2 Atrix Laboratories
5.2.1 Background
5.2.2 Technology
5.2.3 Veterinary applications and partnerships
5.2.4 Future opportunities
5.3 Captec
5.3.1 Background
5.3.2 Technology
5.3.3 Veterinary applications and partnerships
5.3.4 Future opportunities
5.4 CollaGenex
5.4.1 Background
5.4.2 Technology
5.4.3 Veterinary applications and partnerships
5.4.4 Future opportunities
5.5 Embrex
5.5.1 Background
5.5.2 Technology
5.5.3 Veterinary applications and partnerships
5.5.4 Future opportunities
5.6 Emisphere Technologies
5.6.1 Background
5.6.2 Technology
5.6.3 Veterinary applications and partnerships
5.6.4 Future opportunities
5.7 Endorex
5.7.1 Background
5.7.2 Technology
5.7.3 Veterinary applications and partnerships
5.7.4 Future opportunities
5.8 Fuisz Technologies
5.8.1 Background
5.8.2 Technology
5.8.3 Veterinary applications and partnerships
5.8.4 Future opportunities
5.9 Mycogen
5.9.1 Background
5.9.2 Technology
5.9.3 Animal health applications
5.10 PowderJect
5.10.1 Background
5.10.2 Technology
5.10.3 Potential applications in animal health
5.11 Scherer
5.11.1 Background
5.11.2 Technology
5.11.3 Structure of Zydis agreements
5.11.4 Animal health applications
5.12 Virus Research Institute
5.12.1 Background
5.12.2 Technology
5.12.3 Veterinary applications and partnerships
5.12.4 Future opportunities

LIST OF TABLES
Table 2.1 Delivery methods for fipronil, imidacloprid and lufenuron

Table 3.1 Developments in human drug delivery technology

Table 5.1 Companies, technologies and animal health involvements
Table 5.2 Aquila Biopharmaceuticals financial results, 1996-1997
Table 5.3 Atrix financial results, 1995-1997
Table 5.4 Fernz Group sales, 1996-1997
Table 5.5 CollaGenex Pharmaceuticals financial results, 1996-1997
Table 5.6 Embrex financial results, 1996-1997
Table 5.7 Emisphere financial results, 1995-1997
Table 5.8 Endorex financial results, 1997 and cumulative
Table 5.9 Fuisz Technologies financial results, 1996-1997
Table 5.10 Mycogen financial results, 1996-1997
Table 5.11 PowderJect interim financial results, 1996/1997-1997/1998
Table 5.12 R P Scherer financial results, 1995-1997
Table 5.13 Virus Research Institute financial results, 1995-1997